Extemporaneous FORMULATION - moh.gov.my

1 ExtemporaneousFORMULATIONPHARMACEUTICAL SERVICES DIVISIONM inistry of Health MalaysiaPHARMACEUTICAL SERVICES DIVISIONM inistry of Health MalaysiaPharmaceutical Services DivisionMinistry of Health MalaysiaLot 36, Jalan Universiti,46350 Petaling Jaya, : 03-78413200 Fax: 03-79682222/79682268 Extemporaneous FORMULATION , MOH 2015 Pharmaceutical Services Division,Ministry of Health MalaysiaLot 36, Jalan Universiti,46350 Petaling Jaya, edition was Extemporaneous Formulary MOH RIGHTS RESERVEDNo part of this publication may be reproduced, stored or transmitted in any form or by any means whether electronic, mechanical, photocopying, tape, recording or other without permission from the Senior Director of Pharmaceutical Services, Ministry of Health Negara MalaysiaExtemporaneous FORMULATION .

2 Ministry of Health SERVICES DIVISIONM inistry of Health MalaysiaPHARMACEUTICAL SERVICES DIVISIONM inistry of Health MalaysiaEDITORIAL BOARDP atronAbida Haq binti Syed M. HaqDirector of Pharmacy Practice & Development,Pharmaceutical Services Division, MOHA dvisorRosminah binti Mohd DinPharmaceutical Services Division, MOHE ditorsNurul Adha binti Othman Pharmaceutical Services Division, MOHRabi ah binti Mamat Hospital SelayangNoor Liyana YusupPharmaceutical Services Division, MOHC ontributorsNoor Haslina binti Othman - Hospital Raja Prempuan Zainab IINik Nuradlina binti Nik Adnan - Institut Kanser NegaraChan May Yee - Hospital Kuala LumpurChuo Sing Hong - Hospital SibuCynthia Hee Xiao Ying - Hospital Pulau PinangDarshini Siwanandan - Hospital Sungai BulohJanice Lee Siaw Vun - Hospital Wanita & Kanak-Kanak Sabah Khoo Sze Ni - Hospital Raja Permaisuri BainunNg See Yee - Hospital Sultanah BahiyahZaitun binti Mohd Saman - Hospital Pakar Sultanah FatimahAsmahani Ramelan - Hospital Tengku Ampuan Rahimah.

3 KlangTeoh Ai Luan - Hospital Pulau PinangAzhani Kamarudin - Hospital Sungai BulohNabilah Mohamad Shohaime - Hospital PutrajayaGurvinderjit Kaur - Hospital Kuala LumpurCONTENTSINTRODUCTION ..1 OBJECTIVE ..1 POLICY ..2 CONSIDERATIONS FOR PREPARING Extemporaneous COMPOUNDS ..3 WORK FLOW CHART 1: SOURCING THE COMPOUNDING FORMULARY LIST OF Extemporaneous PREPARATION MEDICINES ..5 CHECKLIST 1: SOURCING THE COMPOUNDING FORMULARY LIST OF Extemporaneous PREPARATION MEDICINES ..6 WORK FLOW CHART 2: HANDLING OF PRESCRIPTIONS WITH Extemporaneous PREPARATION MEDICINES IN THE PHARMACY.

4 7 STANDARD LABEL DESIGN & WORKSHEET REQUIREMENTS FOR Extemporaneous PREPARATIONS ..8 CHECKLIST 2: HANDLING OF PRESCRIPTIONS WITH Extemporaneous PREPARATION MEDICINES IN THE PHARMACY ..91. ACETAZOLAMIDE SUSPENSION 25MG/ML ..102. ALLOPURINOL SUSPENSION 20MG/ML ..113. ALPRAZOLAM SUSPENSION 1MG/ML ..12 4. AMIODARONE SUSPENSION 40MG/ML ..135. AMLODIPINE SUSPENSION 1MG/ML ..146. ATENOLOL SUSPENSION 2MG/ML ..157. BACLOFEN SUSPENSION 5MG/ML ..168. BACLOFEN SUSPENSION 10MG/ML ..179. CAFFEINE CITRATE SOLUTION 10MG/ML ..1810. CAPTOPRIL SYRUP 1MG/ML ..1911. CAPTOPRIL SOLUTION 1MG/ML.

5 2012. CARBIDOPA/LEVODOPA (SINEMET ) SUSPENSION CARBIDOPA/5MG LEVODOPA/ML ..2113. CARVEDILOL SUSPENSION ..2214. CARVEDILOL SUSPENSION 1 CHLOROQUINE SUSPENSION 15MG/ML ..2416. CITRIC ACID 25% ..2517. CLONAZEPAM SUSPENSION ..2618. CLOPIDOGREL SUSPENSION 5MG/ML ..2719. DAPSONE SUSPENSION 2MG/ML ..2820. DEXAMETHASONE SUSPENSION ..2921. DIPYRIDAMOLE SUSPENSION 10MG/ML ..3022. ENALAPRIL SUSPENSION ..3123. ENALAPRIL SUSPENSION 1MG/ML ..3224. FERRIC AMMONIUM CITRATE 400MG/5ML MIXTURE ..3325. FOLIC ACID SUSPENSION 1MG/ML ..3426. GABAPENTIN SUSPENSION 100MG/ML.

6 3527. GLYCOPYRROLATE SYRUP ..3628. HYDROCHOLOROTHIAZIDE SUSPENSION 5MG/ML ..3729. INDOMETHACIN SYRUP 5MG/ML ..3830. ISONIAZID SYRUP 10MG/ML ..3931. LABETALOL SYRUP 10MG/ML ..4032. LABETALOL SYRUP 40MG/ML ..4133. LANSOPRAZOLE SUSPENSION 3MG/ML ..4234. LORAZEPAM SYRUP ..4335. METHYLCELLULOSE SUSPENDING AGENT 1% ( ) ..4436. METOPROLOL SUSPENSION 10MG/ML ..4537. MIDAZOLAM SYRUP 2MG/ML ..4638. NIFEDIPINE SUSPENSION 1MG/ML ..4739. NIFEDIPINE SUSPENSION 4MG/ML ..4840. NITROFURANTOIN SUSPENSION 10MG/ML ..4941. OMEPRAZOLE SUSPENSION 2MG/ML ..5042. PANTOPRAZOLE 2MG/ML.

7 5143. PENTOXIFYLLINE SOLUTION 20 PHENOBARBITONE SUSPENSION 10MG/ML ..5345. PHYTOMENADIONE (VITAMIN K1) LIQUID 1MG/ML ..5446. PROPRANOLOL SUSPENSION ..5547. PROPRANOLOL SUSPENSION 1MG/ML ..5648. PYRAZINAMIDE SUSPENSION 10MG/ML ..5749. PYRAZINAMIDE SYRUP 100MG/ML ..5850. RIFAMPICIN SYRUP 10MG/ML ..5951. RIFAMPICIN SUSPENSION 25MG/ML ..6052. SILDENAFIL SUSPENSION ..6153. SPIRONOLACTONE SYRUP ..6254. SPIRONOLACTONE SYRUP ..6355. TRIMETHOPRIM SUSPENSION 10MG/ML ..6456. TRIMETHOPRIM SYRUP 10MG/ML ..6557. URSODEOXYCHOLIC ACID SUSPENSION 50MG/ML ..6658. VERAPAMIL SUSPENSION 50MG/ML.

8 6759. VERAPAMIL SUSPENSION 8MG/ML ..68 ABBREVIATIONS ..691 INTRODUCTIONC ompounding of pharmaceutical formulations remain as the core skill of pharmacists and this manual is produced to include well referenced recipes that are easy to prepare, use readily available ingredients, have the longest expiry date possible and when necessary, provide more than one strength of FORMULATION to accommodate the unique needs of different groups of have been made to search for substantiated references in producing this manual of Extemporaneous preparations.

9 However, the lists of compounded items in this manual are not exhaustive. Preparations included in the manual are for ingredients available commercially but not in the required dosage form for therapy and thus, necessitate Extemporaneous committee has made all reasonable efforts to confirm the accuracy of the information contained in the manual and to present the best practices as identified at the time of its completion. Formulations are only included where there is existence of published formulations and associated stability use of this manual requires knowledge based interpretation by healthcare professionals and is intended solely for use by pharmacists in healthcare facilities.

10 All information contained in the manual has been provided with the sole intention that it be readily accessible for pharmacist s information and as a guide for preparing Extemporaneous preparations that may be standardise formulations of Extemporaneous preparations and practice in healthcare Always consider the use of commercially available products as far as possible. 2. If no suitable commercial product exists, consider a therapeutic alternative that is available in a suitable dosage form. This must be discussed with the physician.